Camilla Jensen

2.3k total citations · 1 hit paper
16 papers, 828 citations indexed

About

Camilla Jensen is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pharmacology. According to data from OpenAlex, Camilla Jensen has authored 16 papers receiving a total of 828 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in Camilla Jensen's work include Diabetes Treatment and Management (8 papers), Pharmacology and Obesity Treatment (5 papers) and Metabolism, Diabetes, and Cancer (5 papers). Camilla Jensen is often cited by papers focused on Diabetes Treatment and Management (8 papers), Pharmacology and Obesity Treatment (5 papers) and Metabolism, Diabetes, and Cancer (5 papers). Camilla Jensen collaborates with scholars based in Denmark, United States and United Kingdom. Camilla Jensen's co-authors include Thomas A. Wadden, Birgitte Claudius, Gary Zammit, Louis J. Aronne, Gary D. Foster, Russell Rosenberg, Adam Blackman, Emmanuel Mignot, Danny Sugimoto and Domenica Rubino and has published in prestigious journals such as Journal of the American College of Cardiology, Diabetes Care and Journal of the American Society of Nephrology.

In The Last Decade

Camilla Jensen

16 papers receiving 802 citations

Hit Papers

Effect of liraglutide 3.0 mg in individuals with obesity ... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
    2016 356 citations Adam Blackman, Gary D. Foster et al. International Journal of Obesity profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Camilla Jensen Denmark 8 496 377 343 191 107 16 828
Everton Rowe United States 12 731 1.5× 567 1.5× 273 0.8× 386 2.0× 57 0.5× 26 1.2k
Louise Færch Denmark 7 720 1.5× 414 1.1× 239 0.7× 279 1.5× 29 0.3× 16 930
Anna Koroleva United States 6 617 1.2× 498 1.3× 254 0.7× 249 1.3× 36 0.3× 12 863
Signe Olrik Rytter Wallenstein United States 5 537 1.1× 428 1.1× 214 0.6× 245 1.3× 34 0.3× 9 717
Bruno Delafont United Kingdom 9 368 0.7× 100 0.3× 220 0.6× 238 1.2× 47 0.4× 19 894
Brandon K. Bergman United States 5 924 1.9× 393 1.0× 299 0.9× 397 2.1× 64 0.6× 12 1.2k
Mads Frederik Rasmussen Denmark 7 838 1.7× 480 1.3× 344 1.0× 378 2.0× 170 1.6× 7 1.1k
Federico C. Pérez Manghi United Kingdom 3 877 1.8× 375 1.0× 283 0.8× 383 2.0× 64 0.6× 3 1.1k
Sirel Gurbuz United States 5 677 1.4× 430 1.1× 341 1.0× 235 1.2× 73 0.7× 7 921
Bernard Job France 4 246 0.5× 339 0.9× 126 0.4× 54 0.3× 47 0.4× 7 619

Countries citing papers authored by Camilla Jensen

Since Specialization
Citations

This map shows the geographic impact of Camilla Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Camilla Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Camilla Jensen more than expected).

Fields of papers citing papers by Camilla Jensen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Camilla Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Camilla Jensen. The network helps show where Camilla Jensen may publish in the future.

Co-authorship network of co-authors of Camilla Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of Camilla Jensen. A scholar is included among the top collaborators of Camilla Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Camilla Jensen. Camilla Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Pérgola, Pablo E., Michael H. Davidson, Camilla Jensen, et al.. (2023). Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3–5: An Analysis of a Randomized Trial (RESCUE). Journal of the American Society of Nephrology. 35(1). 74–84. 13 indexed citations
2.
3.
Cornel, Jan H., Michael H. Davidson, Peter Libby, et al.. (2022). Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio. JAMA Cardiology. 8(2). 177–177. 27 indexed citations
4.
5.
Adamstein, Nicholas, Jan H. Cornel, Peter Libby, et al.. (2022). The effect of ziltivekimab on the neutrophil-lymphocyte ratio: analysis from RESCUE. European Heart Journal. 43(Supplement_2). 1 indexed citations
6.
Verma, Subodh, Melanie J. Davies, John Deanfield, et al.. (2021). CONTINUED TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 4 TRIAL. Journal of the American College of Cardiology. 77(18). 1608–1608. 1 indexed citations
7.
Rubino, Domenica, Niclas Abrahamsson, Melanie J. Davies, et al.. (2021). Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4). Journal of the Endocrine Society. 5(Supplement_1). A63–A64. 3 indexed citations
8.
Garvey, W. Timothy, Andreas L. Birkenfeld, Dror Dicker, et al.. (2020). Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 43(5). 1085–1093. 139 indexed citations
9.
Wadden, Thomas A., Jena Shaw Tronieri, Danny Sugimoto, et al.. (2020). Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity. 28(3). 529–536. 142 indexed citations
10.
Wadden, Thomas A., Jena Shaw Tronieri, Michael Lund, et al.. (2019). SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the Endocrine Society. 3(Supplement_1). 1 indexed citations
11.
Meteran, Howraman, Morten Hostrup, Celeste Porsbjerg, et al.. (2017). Exercise and diet improve asthma controlin non-obese asthma patients - a randomised controlled trial. OA4678–OA4678. 1 indexed citations
12.
Meteran, Howraman, Morten Hostrup, Nina Rica Wium Geiker, et al.. (2017). Effects of Exercise and Diet in Nonobese Asthma Patients—A Randomized Controlled Trial. The Journal of Allergy and Clinical Immunology In Practice. 6(3). 803–811. 63 indexed citations
13.
Blackman, Adam, Gary D. Foster, Gary Zammit, et al.. (2016). Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. International Journal of Obesity. 40(8). 1310–1319. 356 indexed citations breakdown →
14.
Blackman, Adam, Gary D. Foster, Gary Zammit, et al.. (2015). Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in obese individuals with moderate or severe disease: scale sleep apnoea tria. Sleep Medicine. 16. S24–S24. 5 indexed citations
15.
16.
Blackman, Adam, Gary D. Foster, Russell Rosenberg, et al.. (2015). Improvements in sleep apnea endpoints and quality of life are related to the degree of weight loss: Results from the randomized, double-blind scale sleep apnea trial. Sleep Medicine. 16. S211–S212. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Everton Rowe Breakdown of academic impact, for papers by Louise Færch Breakdown of academic impact, for papers by Anna Koroleva Breakdown of academic impact, for papers by Signe Olrik Rytter Wallenstein Breakdown of academic impact, for papers by Bruno Delafont Breakdown of academic impact, for papers by Brandon K. Bergman Breakdown of academic impact, for papers by Mads Frederik Rasmussen Breakdown of academic impact, for papers by Federico C. Pérez Manghi Breakdown of academic impact, for papers by Sirel Gurbuz Breakdown of academic impact, for papers by Bernard Job
Rankless by CCL
2026